Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 52, Issue 11, Pages 1733-1740Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.110.076315
Keywords
Alzheimer disease; beta-amyloid; PET
Funding
- NHMRC [509166, 1011689]
Ask authors/readers for more resources
Imaging of brain beta-amyloid plaques with F-18-labeled tracers for PET will likely be available in clinical practice to assist the diagnosis of Alzheimer disease (AD). With the rapidly growing prevalence of AD as the population ages, and the increasing emphasis on early diagnosis and treatment, brain amyloid imaging is set to become a widely performed investigation. All physicians reading PET scans will need to know the complex relationship between amyloid and cognitive decline, how to best acquire and display images for detection of amyloid, and how to recognize the patterns of tracer binding in AD and other causes of dementia. This article will provide nuclear medicine physicians with the background knowledge required for understanding this emerging investigation, including its appropriate use, and prepare them for practical training in scan interpretation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available